Clinical trial
Effects of Dalfampridine on Cognition in Multiple Sclerosis
NCT02006160 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Dalfampridine on Cognition in Multiple Sclerosis
- Lead sponsor
- State University of New York at Buffalo
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- February 29, 2016
- Enrollment
- 61 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.